Ionis licenses chronic hepatitis B treatments to GSK
28-08-2019
GSK sues Chinese company over Advair Diskus TMs
26-03-2019
GSK seeks to boost oncology repertoire with $5.1bn acquisition
03-12-2018
will barton / Shutterstock.com
Growth in GlaxoSmithKline’s (GSK) vaccines and consumer healthcare divisions has managed to partly counter the impact of generic versions of Advair (fluticasone propionate/salmeterol) on its sales.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
GSK, GlaxoSmithKline, Advair, generics, patent cliff, results, vaccines, Emma Walmsley, Tesaro, R&D
